Gain Therapeutics receives Nasdaq MVLS deficiency notice; must regain compliance by Jan 7, 2025

Gain Therapeutics, Inc.

Nasdaq notified Gain on June 11, 2024, that MVLS was below $50M minimum required for Global Market listing.
Company has 180 days (through Jan 7, 2025) to achieve MVLS >= $50M for ten consecutive business days.
Failure to comply may lead to delisting; company could appeal or apply to transfer to Nasdaq Capital Market.
Gain intends to monitor and take reasonable measures but cannot assure compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.